one8zero8 LLC Acquires Shares of 674 Bio-Rad Laboratories, Inc. (NYSE:BIO)

one8zero8 LLC bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 674 shares of the medical research company’s stock, valued at approximately $221,000.

Other large investors have also made changes to their positions in the company. Wealthfront Advisers LLC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth $342,686,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Bio-Rad Laboratories by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock worth $147,583,000 after acquiring an additional 4,260 shares during the period. Westfield Capital Management Co. LP boosted its position in shares of Bio-Rad Laboratories by 3.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after acquiring an additional 9,584 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories in the third quarter valued at about $83,681,000. Finally, Mawer Investment Management Ltd. increased its position in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after purchasing an additional 84,237 shares during the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on BIO. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $255.34 on Monday. Bio-Rad Laboratories, Inc. has a one year low of $244.00 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The firm’s 50 day moving average price is $311.97 and its 200-day moving average price is $328.00. The firm has a market cap of $7.15 billion, a P/E ratio of -3.93 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.